Vanda Pharmaceuticals' anxiety drug fails Phase III trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 4.05 +0.04 (1.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.01 | 52 Week High | $18.00 | |||
| Open | $4.01 | 52 Week Low | $6.91 | |||
| Day High | $4.13 | P/E | N/A | |||
| Day Low | $3.96 | EPS | $-0.67 | |||
| Volume | 604,826 | |||||
